El-SayedHBennettMELohTMDaviesMG. Retrograde pedal access and endovascular revascularization: a safe and effective technique for high-risk patients with complex tibial vessel disease. Ann Vasc Surg. 2016;31:91–98.
2.
WalkerCMMustaphaJZellerTet al. Tibiopedal access for crossing of infrainguinal artery occlusions: a prospective multicenter observational study. J Endovasc Ther. 2016;23:839–846.
3.
DayamaATsilimparisNKolakowskiSet al. Clinical outcomes of bypass-first versus endovascular-first strategy in patients with chronic limb-threatening ischemia due to infrageniculate arterial disease. J Vasc Surg. 2019;69:156–163.
4.
GoodneyPPBeckAWNagleJet al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54–60.
5.
KatibNThomasSDLennoxAFet al. An endovascular-first approach to the treatment of critical limb ischemia results in superior limb salvage rates. J Endovasc Ther. 2015;22:473–481.
6.
AgarwalSSudKShishehborMH. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients. J Am Coll Cardiol. 2016;67:1901–1913.
7.
MustaphaJGrayWMartinsenBJet al. One-year results of the LIBERTY 360 Study: evaluation of acute and midterm clinical outcomes of peripheral endovascular device interventions. J Endovasc Ther. 2019;26:143–154.
8.
DormandyJARutherfordRB. Management of peripheral arterial disease (PAD). TASC Working Group: TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1pt 2):S1–S296.
9.
StavroulakisKBorowskiMTorselloGet al; CRITISCH Collaborators. One-year results of first-line treatment strategies in patients with critical limb ischemia (CRITISCH Registry). J Endovasc Ther. 2018;25:320–329.
JonesWSKrucoffMWMoralesPet al. Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements. J Vasc Surg. 2018;67:637–644.e30.
13.
SchneiderPALairdJRTepeGet al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT randomized SFA trial. Circ Cardiovasc Interv. 2018;11:e005891. doi:10.1161/CIRCINTERVENTIONS.117.005891
14.
KrishnanPFariesPNiaziKet al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136:1102–1113.
15.
GrayWAKeirseKSogaYet al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention. Lancet. 2018;392:1541–1551.
16.
AnandSSBoschJEikelboomJWet al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial. Lancet. 2018;391:219–229.
17.
WestinGGArmstrongEJBangHet al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival rates in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682–690.
